Skip to content

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safey of AST-001 Followed by an Open-Label Extension Treatment Period in Children with Autism Spectrum Disorder

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safey of AST-001 Followed by an Open-Label Extension Treatment Period in Children with Autism Spectrum Disorder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0008915
Enrollment
160
Registered
2023-10-30
Start date
2023-08-29
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Main study(0~12 weeks) Experimental: AST-001 Comparator: Placebo of AST-001 Extension study(12~24 weeks) Experimental: AST-001 Comparator: AST-001

Sponsors

Astrogen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Those who meet the criteria of diagnostic and statistical manual of mental disorder (DSM)-5 during screening, During screening period, individuals who are diagnosed with ASD through ADI-R assessment, Subject with a CGI-S score of 4 or higher as a result of Clinical Global Impression(CGI) evaluation during baseline visit(visit 2), Subject or/and legally authorized representative voluntarily agreed to participate in this clinical trial and provided their informed consent by signing the written consent form, In case of subjects who were receiving non-pharmacological therapy at the time of screening, the non-pharmacological therapy lasted at least 3 months prior to participation in screening and is expected to be sustainable during this clinical trial, Subject whose legally authorized representative is able to participate in the provision of reliable information about the subject’s condition, execute all scheduled site visits, oversee IP administration, fully understand and speak Korean, and conduct survey evaluation regarding the subject

Exclusion criteria

Exclusion criteria: At the time of screening, subject has the medical history, concomitant condition, or surgical history, During the screening period, uncontrolled medical conditions, During the screening period, display of severe self-harm or injury to others that requires medical treatment, determined by investigator, At the time of screening, weight over 60kg, Inappropriate to participate in the trial determined by investigator

Design outcomes

Primary

MeasureTime frame
K-VABS-II (Korean-Vineland Adaptive Behavior Scale-II)

Secondary

MeasureTime frame
CGI (Clinical Global Impression);SRS-2 (Social Responsiveness Scale-2);K-PSI-4-SF (Korean-Parenting Stress Index-4th Edition Short Form)

Countries

Korea, Republic of

Contacts

Public ContactYoo-Sook Joung

Samsung Medical Center

yschoung@skku.edu+82-2-3410-3589

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026